Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618512 | 0.94 | USP30 (0.41) | USP30PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL17618615 | 0.94 | USP30 (0.41) | USP30PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL19365746 | 0.94 | USP30 (0.41) | USP30PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL19704835 | 0.90 | USP30 (0.43) | USP30PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL19706194 | 0.86 | THRB (0.41) | USP30PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL19706087 | 0.85 | HDAC2 (0.42) | USP30LRRK2GPR6HSD11B1MAP4K1 | |
| SCHEMBL19699068 | 0.85 | FAAH (0.38) | USP30FAAHHSD11B1 | |
| SCHEMBL19365376 | 0.83 | USP30 (0.45) | USP30PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL17618586 | 0.83 | USP30 (0.45) | USP30PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL17618514 | 0.83 | USP30 (0.45) | USP30PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | USP30 119/4885PDE4D 2188/4885PDE4A 2267/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | USP30 119/4885PDE4D 2188/4885PDE4A 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.